Pharma and Healthcare Insight

Pharma & Healthcare Insight brings you analysis of regional trends, regulatory changes, projects and investments plus competitive intelligence on the growth strategies of leading companies in the sector

See Prices or Subscribe

Key stories from this month's issue...

Industry Trend Analysis - Drug Pricing Pressures Will Remain High - JUNE 2016

Americas May 2016 / Brazil / Industry

The Brazilian authorities will continue to place downward price pressures on medicines, resulting in profit declines for drugmakers. Although the latest drug pricing regulation is a relatively fair and transparent mechanism, Brazil's competitive pharmaceutical market will provide an increasingly challenging operating environment for drugmakers.


Industry Trend Analysis - Asia To Be A Key Region For Dengue Vaccine - JUNE 2016

Asia May 2016 / Asia / Industry

The burden of dengue in the Asia Pacific regin will continue to remain high, creating a demand for Sanofi's dengue fever vaccine. The company will benefit from the lack of competitors in this space, with Takeda Pharmaceutical's TAK-003 still in Phase II trials. To fully capture the rewards in the region, the innovative pharmaceutical firm will have to navigate the high levels of out-of-pocket health spending in the region, which raises challenges in affordability.


Industry Trend Analysis - Attractiveness To Remain Limited Despite Improvements To Healthcare - JUNE 2016

Emerging Europe May 2016 / Hungary / Industry

Hungary's pharmaceuticals and healthcare market will remain a limited prospect for investment due to the systemic underfunding of the healthcare sector. While improvements to healthcare provision and accessibility are likely to increase demand for medicines, the country's revenue earning opportunities remains modest in comparison to neighbouring markets.


Industry Trend Analysis - Epidemiological Profile Will Continue To Attract Drugmakers - JUNE 2016

Middle East & Africa May 2016 / Ethiopia / Industry

Ethiopia's evolving epidemiological profile will provide increased revenue earning opportunities for international drugmakers. The rising disease burden, combined with government incentives to improve access to treatment, will support a greater multinational presence over the long term. Although generic products hold a dominant share of the market in both value and volume terms, due to a growing middle class and subsequent lifestyle changes, and the subsequent shifting disease profile towards non-communicable diseases, the opportunity for high-value innovative drugs is growing. Highlighting this, blockbuster products including Seretide (salmeterol and fluticasone propionate), Crestor (rosuvastatin) and Nexium (esomeprazole) are all registered in the country.


Industry Trend Analysis - Generic Drug Prices Will Continue To Fall - JUNE 2016

Western Europe May 2016 / Germany / Industry

Downward pressure on the prices of generic medicines in Germany as a result of tenders raising the level of competition, and the ultimate commoditisation of off-patent medicines, draws attention to the inherent challenges for generic drugmakers looking to profit from the government's focus on cost-containment within the healthcare sector. While the loss of value in the patented drugs segment will not translate into an equivalent gain for generic sales, significant expansion of the latter, as a percentage of total sales will correlate with a steady contraction in the former.